ImetelChat

Let's get Imetelstat over the finish line. It is now a binary decision, either the FDA approves (most likely) or the FDA denies. Denial would be a surprise considering 12 YES ODAC votes. Also, the integrity of the FDA would be questioned. The FDA (as far as I can tell) has never rejected an ODAC po...

To KTA -- May I point out that ImetelChat is a chatroom that is designed for science, medical progress and opinions based upon future projections. It not designed to be a scientific journal on the high end or a place for a character assassin on the low end as you are using it on the low end. Your l...

By the short run, I mean the time between today and June 16th. I am hoping that Imetelstat gets approved in that timeframe. If it does not the future of Geron will be very much in doubt after years of successful trails and meeting patients' unmet needs. I believe the FDA will approve, but the FDA's...

The Die is Cast on or before June 16th It now a binary decision, either the FDA approves (most likely) or the FDA denies. Denial would be a surprise considering 12 YES ODAC votes. Also, the integrity of the FDA would be questioned. Geron (obviously) is a one drug company at this point in time. Imet...

The 12 YES votes from ODAC should prevail. No one trusts the FDA after their "devil's advocate" presentation at ODAC's March 14th meeting. Some think there is an "effort" by big pharma to prevent FDA approval of Imetelstat and that is holding the price down. It could shoot up rapidly (toward $10 as...

Tomorrow's (May 9) shareholder meeting may present more information for us to dissect. I don't see anything preventing Imetelstat's NDA approval, that is honest and above board. (No shenanigans or conspiracies that are credible) Anything is possible in the world of Geron. However, as far as I can t...

PPS of Geron almost = to PPS of MAIA ======================== NYSE American - Nasdaq Real Time Price•USD MAIA Biotechnology, Inc. (MAIA) Following 3.3900+0.1100(+3.3537%) As of 2:05 PM EDT. Market Open. ===================== NasdaqGS - Nasdaq Real Time Price•USD Geron Corporation (GERN) Following 3...

We cannot separate Geron from MAIA at this point in time. There is too much common history between them with similar goals. I believe both companies will be successful as important factors in the development of treatments and cures for a variety of cancers --- the whole spectrum from the simplest o...

For whatever reason, money (at the moment) is flowing out of Geron and into MAIA (tied to each other by Sergei & patent considerations). What is happening at MAIA (solid cancers with delivery systems) that appears to be so interesting? Does a Geron approval from the FDA open the doors for MAIA to g...

There is much to follow as Geron is near FDA approval, MAIA gets major tail winds from Imetelstat and TD Cowen sees $10 for Geron's PPS. Also, there will be inputs from MD Anderson and the U of Texas (Partners at new state of the art cancer center in Austin). Next week will be very interesting. ===...

In John Scarlett's own words: Geron continues to work closely with the FDA. The NDA (New Drug Application) is under complete review and Geron is "preparing for a successful launch". I don't see any foul-ups, conspiracies or shenanigans at this point in time. Approval looks ensured, but it is not a ...

More Information From May 2, 2024 ======================= Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights May 02, 2024 June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS FOSTER CI...

Quick Summary of Today's Remarks ================= Path to Commercial Value Creation, Geron is well-positioned for a successful U.S. launch upon potential approval • Commercial team fully onboarded with completion of hiring of the U.S. sales force in April 2024 • Enhanced capabilities and coordinate...

There is too much here, once the FDA grants approval, for Geron to go it alone. I expect partners, collaborators, combinations and associates at several levels. We all expect FDA approval after the 12 YES vote recommendation from ODAC. However, some potential investors are apparently taking a wait ...

The focus is now on Geron's $10 PPS. The science, successful trials, patients' needs and combination potential are all important factors. Surprise: Geron Corporation (GERN) Following 4.0400 +0.2500 (+6.5965%) As of 11:08 AM EDT. Market Open. ---------------------------------------------------------...

The certain (almost) approval from the FDA of Imetelstat is blowing very favorable tail winds behind MAIA. Are Geron & MAIA 'tied at the hip' in some ways? The markets are telling us something, but we don't know precisely what. =================== MAIA Biotechnology, Inc. (MAIA) Follow 2.9400 +0.26...

The most obvious connection between Geron and MAIA is Sergei. I suspect when Imetelstat finally gets FDA approval (blood cancers), that will be very beneficial to THIO --- solid cancer treatment and perhaps accelerated approvals for MAIA/THIO. Other connections are patents, MD Anderson and the Univ...

Update (April 26)
================

Geron Corporation (GERN)
3.8000+0.2400(+6.7416%)
As of 12:13 PM EDT. Market Open.

==================
MAIA Biotechnology, Inc. (MAIA)
2.7601+0.0801(+2.99%)
As of 12:06 PM EDT. Market Open.

The side effect dangers (specifically Cytopenias and Nuetropenias) were discussed on March 14th. ODAC and others (blood cancer experts) put this problem into proper prospective (manageable and can be eliminated in a short time). The problem seems to be that not all benefit. The side effects can be ...

There is much activity in both Geron's and MAIA's PPS. IMHO both will be great successes and will find some ways to work together for common goals. Today they are moving in opposite directions. ------------------------------------------------------------- NYSE American - Nasdaq Real Time Price•USD ...